The 2014 News Archive of Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia

2014 News Archive

Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

London, UK - 20 November 2014 -Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has initiated a Phase IIa study in tinnitus subjects with its lead compound AUT00063. This proof of concept study (called the QUIET-1 study, QUest In Eliminating Tinnitus) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to reduce the symptoms of tinnitus, which is an area of significant unmet medical need. 

Read more


Autifony Therapeutics supports art exhibition ‘Reassembling the self’, focused on schizophrenia, together with Universities of Manchester and Newcastle

London, UK – 16 Sept 2014 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and for schizophrenia, announced that it is supporting the art exhibition ‘Reassembling the self’ focused on schizophrenia, which opens today at GV Art, the leading art-science gallery, in London. Autifony’s support reflects the company’s belief that the understanding of schizophrenia as a condition needs to be increased. The development of new and better drug treatments will require a patient-centric approach in addition to the advances being made in basic neuroscience. Autifony is joined in its support of the exhibition by the Universities of Manchester and Newcastle, with whom it is collaborating on a novel approach to treatment of schizophrenia, and by the Technology Strategy Board which is part-funding the programme.

Read more


Autifony Therapeutics shortlisted in top five biotech SMEs in Europe by EuropaBio

London, UK - 01 Sept 2014 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been selected by EuropaBio as one of the top five biotech SMEs in Europe, who will compete to win the 5th annual Most Innovative EU Biotech SME Award.

Read more


Autifony Therapeutics hosts symposium ‘Schizophrenia: a treatable brain disorder’ at British Association for Psychopharmacology

London, UK – 21st July 2014 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and serious disorders of the nervous system, today hosted a satellite symposium at the British Association for Psychopharmacology 40th Anniversary Summer Meeting to raise the profile of its pioneering new schizophrenia programme, now in preclinical development.

Read more


Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Award follows successful completion of Phase I

London, UK – 4 June 2014 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board. Autifony will be sponsor of the clinical study, with Professor Deborah Hall at The University of Nottingham and National Institute for Health Research (NIHR) Nottingham Hearing Biomedical Research Unit (BRU) as lead academic collaborator.

Read more